VASILIOS VASILAKOPOULOS
Kozani General Hospital- Cardiology Department
Title: PHARMACEUTICAL RECONSTRUCTION OF PATIENTS WITH PAROXYSMAL ATRIAL FIBRILATION WITHOUT STRUCTURAL HEART DISEASE. THE EXPERIENCE OF INTRAVENUAL FLEKAINID.
Biography
Biography: VASILIOS VASILAKOPOULOS
Abstract
Introduction: Flecainide, administered iv, is highly effective and safe in relieving the recent onset of atrial fibrillation (VT).
Purpose: Flecainide intravenous solution is a relatively new therapeutic approach to atrial fibrillation reduction. This study was designed to record the experience of our clinic from its use in patients with paroxysmal atrial fibrillation.
Material - Method: Intravenous flecainide was administered to 16 consecutive patients (10 men - 6 women), mean age 67.8 ± 14 years, who were admitted to the Cardiology Clinic of the General Hospital of Kozani, due to paroxysmal atrial fibrillation, while exclusion criteria (SN, NYHA II-IV, HCM, second or third degree atrioventricular block, left ventricular block known as CKD). Intravenous flecainide 150 mg / 15mL was administered at a dose of 2 mg / Kg within 10 minutes and the administration time was 10-15 minutes, preceded by oral beta-blocker. Patients were monitored and the recovery time as well as the occurrence of proarrhythmic phenomena were recorded. All patients underwent a cardiac ultrasound and any comorbidities were recorded. Patients were monitored for 45 min, 60 min, 3-6 hours, 6-12 hours, 12-24 hours and 24-36 hours for any side effects.
Results: Of the 16 patients, 12 (75%) recovered with intravenous flecainide in combination with β-blocker. The remaining 4 patients (25%) did not recover with the above combination, although the intravenous drip infusion of flecainide followed, at which time an electrical reduction was performed. The average reduction time for the former was 9 ± 6.5 minutes. No proarrhythmic effects were observed in any patient.